Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder

[PR Newswire] – CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements … more

View todays social media effects on PTN

View the latest stocks trending across Twitter. Click to view dashboard

See who Palatin is hiring next, click here to view